A 69-year-old woman attends for annual review with type 2 diabetes, hypertension, osteoarthritis affecting both knees and hands, and recurrent urinary tract infections. She takes metformin, ramipril, amlodipine, paracetamol, ibuprofen 400mg three times daily, and recently completed a course of trimethoprim. She reports good glycaemic control but mentions her blood pressure readings at home are occasionally elevated. Her recent blood results show: eGFR 52 ml/min/1.73m² (previously 68 six months ago), potassium 5.2 mmol/L, HbA1c 52 mmol/mol. Which medication interaction represents the GREATEST current risk?
Q12
A 72-year-old man with chronic kidney disease stage 4 (eGFR 24 ml/min/1.73m²), type 2 diabetes, hypertension, and gout presents for medication review. His current medications include: metformin 1g twice daily, gliclazide 80mg twice daily, ramipril 10mg once daily, amlodipine 10mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and omeprazole 20mg once daily. His HbA1c is 58 mmol/mol, and he reports intermittent episodes of feeling 'shaky and sweaty'. Which medication requires MOST urgent modification?
Q13
A 67-year-old woman with multimorbidity attends for a comprehensive medication review. She has six chronic conditions: heart failure, atrial fibrillation, type 2 diabetes, hypothyroidism, osteoporosis, and depression. She takes 11 regular medications. According to NICE guidance on multimorbidity (NG56), which approach is MOST important when prioritising her care during this consultation?
Q14
A practice pharmacist is developing a protocol for identifying patients who would benefit from structured medication reviews. According to the NHS England Structured Medication Review and Medicines Optimisation guidance, which of the following criteria would indicate the highest priority for a structured medication review?
Q15
You are reviewing prescribing data for your practice as part of a medication safety initiative. You identify a 69-year-old man with heart failure (LVEF 38%), type 2 diabetes, CKD stage 3b (eGFR 36 ml/min/1.73m²), and gout who has been prescribed allopurinol 300mg daily, ramipril 10mg daily, spironolactone 25mg daily, and furosemide 40mg daily. His most recent blood results show: sodium 138 mmol/L, potassium 5.8 mmol/L, urea 12.4 mmol/L, creatinine 165 µmol/L (baseline 158 µmol/L). He is asymptomatic. What is the most appropriate immediate management?
Q16
A 74-year-old woman with moderate Alzheimer's dementia (MMSE 16/30), type 2 diabetes, hypertension, and atrial fibrillation lives alone with support from carers visiting twice daily. Her daughter reports that her mother has become increasingly confused and is now missing medication doses. Current medications include donepezil, memantine, metformin, gliclazide, amlodipine, ramipril, apixaban, and atorvastatin. The daughter asks whether her mother's medications could be simplified. Which medication would it be most appropriate to consider stopping first?
Q17
During a practice-based quality improvement project, you are reviewing prescribing patterns in patients over 75 years taking 10 or more regular medications. You identify that 22% of patients in this group are taking a proton pump inhibitor (PPI) long-term without a documented indication. According to current evidence and guidance on deprescribing PPIs, which patient scenario would be the strongest indication for continuing long-term PPI therapy?
Q18
A 76-year-old man with atrial fibrillation, heart failure (NYHA class II), type 2 diabetes, and benign prostatic hyperplasia attends for review. His medications include apixaban 5mg twice daily, bisoprolol, ramipril, metformin, empagliflozin, and tamsulosin. He reports two falls in the past month, both occurring at night when getting up to use the toilet. He describes feeling dizzy and nearly fainting. His lying blood pressure is 136/78 mmHg and standing blood pressure (after 1 minute) is 104/62 mmHg. What is the most likely cause of his orthostatic hypotension and falls?
Q19
You are conducting a medication review for a 71-year-old woman with multimorbidity who takes 12 regular medications. She reports good adherence but admits she sometimes gets confused about which tablets to take and when. Her medication regimen includes twice-daily, three times daily, and once-daily medications, with some to be taken with food and others on an empty stomach. Which intervention has the strongest evidence base for improving medication adherence in patients with complex regimens?
Q20
A 70-year-old man attends for a medication review. He has COPD (post-bronchodilator FEV1 44% predicted), ischaemic heart disease, peripheral arterial disease, and has had two previous strokes. His current medications include aspirin, clopidogrel, atorvastatin, bisoprolol, ramipril, tiotropium, and salbutamol. He smoked 30 cigarettes daily until his last stroke 3 years ago and has not smoked since. What is the most appropriate modification to his antiplatelet therapy at this stage?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 11: A 69-year-old woman attends for annual review with type 2 diabetes, hypertension, osteoarthritis affecting both knees and hands, and recurrent urinary tract infections. She takes metformin, ramipril, amlodipine, paracetamol, ibuprofen 400mg three times daily, and recently completed a course of trimethoprim. She reports good glycaemic control but mentions her blood pressure readings at home are occasionally elevated. Her recent blood results show: eGFR 52 ml/min/1.73m² (previously 68 six months ago), potassium 5.2 mmol/L, HbA1c 52 mmol/mol. Which medication interaction represents the GREATEST current risk?
A. The combination of metformin and trimethoprim increasing lactic acidosis risk
B. The interaction between ramipril and ibuprofen affecting renal function (Correct Answer)
C. The combination of amlodipine and ibuprofen reducing antihypertensive efficacy
D. The interaction between ramipril and amlodipine causing excessive hypotension
E. The combination of paracetamol and ibuprofen increasing hepatotoxicity risk
Explanation: ***The interaction between ramipril and ibuprofen affecting renal function***
- Combining an **ACE inhibitor** (ramipril) with an **NSAID** (ibuprofen) significantly impairs renal autoregulation by causing **efferent arteriolar vasodilation** (ramipril) and **afferent arteriolar vasoconstriction** (ibuprofen).
- This
Question 12: A 72-year-old man with chronic kidney disease stage 4 (eGFR 24 ml/min/1.73m²), type 2 diabetes, hypertension, and gout presents for medication review. His current medications include: metformin 1g twice daily, gliclazide 80mg twice daily, ramipril 10mg once daily, amlodipine 10mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and omeprazole 20mg once daily. His HbA1c is 58 mmol/mol, and he reports intermittent episodes of feeling 'shaky and sweaty'. Which medication requires MOST urgent modification?
A. Allopurinol should be increased to 300mg daily for adequate urate control
B. Metformin should be stopped immediately due to risk of lactic acidosis (Correct Answer)
C. Ramipril should be reduced due to advanced chronic kidney disease
D. Gliclazide should be reviewed and reduced due to hypoglycaemia risk
E. Aspirin should be stopped as cardiovascular protection is inadequate at this dose
Explanation: ***Metformin should be stopped immediately due to risk of lactic acidosis***- **Metformin** is primarily cleared by the kidneys and is **contraindicated** when the **eGFR falls below 30 ml/min/1.73m²** (CKD Stage 4). The patient's eGFR is 24.- Continued use in this setting significantly increases the risk of **metformin-associated lactic acidosis (MALA)**, a severe and life-threatening metabolic emergency requiring urgent discontinuation.*Allopurinol should be increased to 300mg daily for adequate urate control*- Increasing **allopurinol** to 300mg in a patient with an **eGFR of 24 ml/min/1.73m²** is inappropriate and risky, as it can lead to severe toxicity, including **allopurinol hypersensitivity syndrome**.- The current dose of **100mg daily** is generally considered the maximum safe dose for patients with this level of **renal impairment**.*Ramipril should be reduced due to advanced chronic kidney disease*- **ACE inhibitors** like **ramipril** are often beneficial in CKD for **renoprotection** and blood pressure control, provided there is no acute kidney injury or severe hyperkalemia.- While renal function and electrolytes require close monitoring, discontinuing metformin due to the immediate and severe risk of **lactic acidosis** takes precedence.*Gliclazide should be reviewed and reduced due to hypoglycaemia risk*- The patient's symptoms of feeling "shaky and sweaty" are classic for **hypoglycaemia**, likely exacerbated by **gliclazide** accumulation due to reduced renal clearance.- While adjusting **gliclazide** is crucial to prevent further hypoglycaemic episodes, the immediate risk of **metformin-associated lactic acidosis** is a higher priority.*Aspirin should be stopped as cardiovascular protection is inadequate at this dose*- **Aspirin 75mg daily** is the standard and effective dose for **secondary prevention** of cardiovascular events, especially in patients with multiple risk factors like this gentleman.- There is no clinical indication to stop aspirin based on its efficacy at this dose, and doing so would remove a crucial component of his cardiovascular protection.
Question 13: A 67-year-old woman with multimorbidity attends for a comprehensive medication review. She has six chronic conditions: heart failure, atrial fibrillation, type 2 diabetes, hypothyroidism, osteoporosis, and depression. She takes 11 regular medications. According to NICE guidance on multimorbidity (NG56), which approach is MOST important when prioritising her care during this consultation?
A. Focus on achieving optimal disease-specific targets for each individual condition
B. Establish the patient's priorities for treatment and quality of life outcomes (Correct Answer)
C. Systematically review medications starting with those prescribed most recently
D. Concentrate on reducing the total number of medications to fewer than 10
E. Prioritise management of conditions with the highest mortality risk first
Explanation: ***Establish the patient's priorities for treatment and quality of life outcomes***- According to **NICE NG56**, the core of multimorbidity management is a **patient-centered approach** that identifies personal goals, values, and desired outcomes.- Shared decision-making ensures that care focuses on improving **quality of life** and reducing **treatment burden**, rather than just following clinical guidelines.*Focus on achieving optimal disease-specific targets for each individual condition*- Managing multiple conditions solely through **single-disease guidelines** often leads to **polypharmacy** and increased risk of adverse drug interactions.- Strict adherence to multiple guidelines may ignore the patient's overall wellbeing and can be practically unfeasible for those with many comorbidities.*Systematically review medications starting with those prescribed most recently*- Medication reviews should focus on assessing **clinical benefit**, **safety**, and **adherence** rather than being dictated by the chronological order of prescription.- The goal is to identify medications that are no longer effective or are causing harm, which may include long-standing prescriptions.*Concentrate on reducing the total number of medications to fewer than 10*- While **deprescribing** is a key goal, there is no evidence-based **arbitrary threshold** (like fewer than 10) for what constitutes an appropriate number of drugs.- Focus should be on the **appropriateness of polypharmacy** and ensuring each medication provides more benefit than harm for that specific patient.*Prioritise management of conditions with the highest mortality risk first*- Focusing only on **mortality risk** (like heart failure) can overlook conditions that significantly impact **functional status** and daily life, such as depression or osteoporosis.- A holistic approach balances survival with the patient's own concerns regarding **symptom control** and daily living activities.
Question 14: A practice pharmacist is developing a protocol for identifying patients who would benefit from structured medication reviews. According to the NHS England Structured Medication Review and Medicines Optimisation guidance, which of the following criteria would indicate the highest priority for a structured medication review?
A. A 58-year-old woman with well-controlled asthma on two inhalers and no recent exacerbations
B. A 72-year-old man taking 15 regular medications for six long-term conditions with recent unplanned hospital admission (Correct Answer)
C. A 65-year-old woman with type 2 diabetes on metformin alone with stable HbA1c for 3 years
D. A 70-year-old man with hypertension on amlodipine with good blood pressure control
E. A 68-year-old woman taking warfarin for atrial fibrillation with stable INR attending anticoagulation clinic regularly
Explanation: ***A 72-year-old man taking 15 regular medications for six long-term conditions with recent unplanned hospital admission***- This patient satisfies critical **NHS England criteria** for high-priority reviews due to **severe polypharmacy** (defined as 10+ medications) and **multimorbidity** (multiple long-term conditions).- A recent **unplanned hospital admission** is a significant indicator of potential **medication-related harm**, adverse drug reactions, or suboptimal disease control, necessitating urgent medication optimization.*A 58-year-old woman with well-controlled asthma on two inhalers and no recent exacerbations*- This patient has a **low medication burden** and is considered clinically stable, which places her at a lower priority for a **Structured Medication Review (SMR)**.- SMRs are primarily focused on patients with complex medication regimens or clinical instability, not routine management of stable, well-controlled conditions.*A 65-year-old woman with type 2 diabetes on metformin alone with stable HbA1c for 3 years*- While diabetes is a chronic condition, **monotherapy** with stable, long-term outcomes does not meet the high-priority criteria for an SMR.- The absence of **polypharmacy**, recent clinical deterioration, or complex medication challenges makes her a lower priority.*A 70-year-old man with hypertension on amlodipine with good blood pressure control*- Single-medication regimens for **hypertension** with achieved target clinical goals are typically managed through routine annual reviews rather than a high-priority SMR.- High priority is reserved for patients with **complex medication needs** where the risk of interactions, adverse effects, or therapeutic failure is higher.*A 68-year-old woman taking warfarin for atrial fibrillation with stable INR attending anticoagulation clinic regularly*- Although warfarin is a **high-risk medication**, this patient is already receiving **specialist oversight** and regular monitoring through a dedicated anticoagulation clinic.- Since her therapy is **stable** and well-managed by a specialized service, she is not the primary target for an urgent primary care SMR compared to a patient with uncontrolled polypharmacy.
Question 15: You are reviewing prescribing data for your practice as part of a medication safety initiative. You identify a 69-year-old man with heart failure (LVEF 38%), type 2 diabetes, CKD stage 3b (eGFR 36 ml/min/1.73m²), and gout who has been prescribed allopurinol 300mg daily, ramipril 10mg daily, spironolactone 25mg daily, and furosemide 40mg daily. His most recent blood results show: sodium 138 mmol/L, potassium 5.8 mmol/L, urea 12.4 mmol/L, creatinine 165 µmol/L (baseline 158 µmol/L). He is asymptomatic. What is the most appropriate immediate management?
A. Stop spironolactone immediately and recheck potassium in 3-5 days (Correct Answer)
B. Reduce ramipril to 5mg daily and recheck electrolytes in 1 week
C. Stop allopurinol temporarily until renal function improves
D. Prescribe calcium resonium 15g three times daily and continue all medications
E. Increase furosemide to 80mg daily to enhance potassium excretion
Explanation: ***Stop spironolactone immediately and recheck potassium in 3-5 days***
- The patient has significant **hyperkalaemia (5.8 mmol/L)** while taking both an **ACE inhibitor (ramipril)** and a **mineralocorticoid receptor antagonist (spironolactone)**, a combination that significantly increases the risk of potassium retention in **CKD stage 3b**.
- Guidelines generally mandate stopping or withholding **spironolactone** if potassium exceeds **5.5 mmol/L** to prevent life-threatening arrhythmias, followed by close monitoring of electrolytes.
*Reduce ramipril to 5mg daily and recheck electrolytes in 1 week*
- While **ACE inhibitors** contribute to hyperkalaemia, **spironolactone** is usually the first medication to be discontinued as it is more likely to cause severe potassium elevation in the setting of renal impairment.
- Maintaining the ACE inhibitor is prioritised for **prognostic benefit** in heart failure unless potassium levels cannot be managed by stopping the aldosterone antagonist alone.
*Stop allopurinol temporarily until renal function improves*
- **Allopurinol** does not directly affect serum **potassium levels**, and its discontinuation would not address the acute risk of hyperkalaemia.
- Stopping allopurinol unnecessarily could trigger an acute **gout flare**, which is undesirable given the patient's existing comorbidities.
*Prescribe calcium resonium 15g three times daily and continue all medications*
- **Calcium resonium** is a potassium-binding resin typically reserved for more severe or refractory hyperkalaemia and does not address the **underlying cause** of the elevation.
- Continuing the offending medications while using an ion-exchange resin is inappropriate management for a patient with a **K+ of 5.8 mmol/L** and significant renal impairment.
*Increase furosemide to 80mg daily to enhance potassium excretion*
- Although **loop diuretics** increase potassium excretion, this is not an appropriate primary treatment for ACEi/MRA-induced hyperkalaemia.
- Increasing the dose of **furosemide** in a patient with **CKD stage 3b** risks further volume depletion and potential worsening of **acute kidney injury**.
Question 16: A 74-year-old woman with moderate Alzheimer's dementia (MMSE 16/30), type 2 diabetes, hypertension, and atrial fibrillation lives alone with support from carers visiting twice daily. Her daughter reports that her mother has become increasingly confused and is now missing medication doses. Current medications include donepezil, memantine, metformin, gliclazide, amlodipine, ramipril, apixaban, and atorvastatin. The daughter asks whether her mother's medications could be simplified. Which medication would it be most appropriate to consider stopping first?
A. Donepezil, as the patient has progressed to moderate dementia
B. Atorvastatin, as the cardiovascular benefit diminishes with advanced age and limited life expectancy
C. Memantine, as combination therapy with donepezil shows limited additional benefit
D. Gliclazide, due to the high risk of hypoglycaemia in a patient with cognitive impairment (Correct Answer)
E. Ramipril, as blood pressure targets can be relaxed in elderly patients with dementia
Explanation: ***Gliclazide, due to the high risk of hypoglycaemia in a patient with cognitive impairment***- **Sulfonylureas** like gliclazide carry a high risk of **hypoglycaemia**, which can worsen **confusion** and increase the risk of **falls** in elderly patients with dementia.- In patients with cognitive impairment who have **irregular eating patterns** or poor medication adherence, the safety risk of hypoglycemia often outweighs the benefits of strict glycemic control. It is a priority for **deprescribing** due to immediate safety concerns.*Donepezil, as the patient has progressed to moderate dementia*- **Donepezil**, a **cholinesterase inhibitor**, is indicated for **mild-to-moderate Alzheimer's disease** and can help maintain cognitive and functional abilities (MMSE 16/30 falls within this range).- Guidelines often recommend continuing **cholinesterase inhibitors** until the late stages of dementia or when the symptomatic benefits are no longer evident, to prevent further decline.*Atorvastatin, as the cardiovascular benefit diminishes with advanced age and limited life expectancy*- While **statin therapy** for **primary prevention** may be reviewed in very frail or elderly patients with limited life expectancy, this patient has multiple cardiovascular risk factors (diabetes, hypertension, AF) implying a need for secondary prevention or significant risk.- Stopping atorvastatin provides a **long-term reduction in cardiovascular protection**, but does not pose the immediate risk of acute harm that **gliclazide** presents with **hypoglycaemia**.*Memantine, as combination therapy with donepezil shows limited additional benefit*- **Memantine** is indicated for **moderate to severe Alzheimer's disease**, which aligns with this patient's MMSE of 16/30.- Combination therapy with an **acetylcholinesterase inhibitor** and **memantine** is supported for moderate-to-severe AD and can help manage **cognitive symptoms** and **behavioral disturbances**, with a relatively low side-effect profile, making it a less urgent medication to stop.*Ramipril, as blood pressure targets can be relaxed in elderly patients with dementia*- While **blood pressure targets** can be relaxed in elderly patients with dementia, **ACE inhibitors** like ramipril are crucial for managing **hypertension**, preventing **stroke**, and mitigating **heart failure** risks, especially in a patient with atrial fibrillation.- Abruptly stopping antihypertensive medication can lead to **rebound hypertension** or other adverse cardiovascular events, which is a significant risk, but still less acute than the immediate danger of **hypoglycaemia** from gliclazide.
Question 17: During a practice-based quality improvement project, you are reviewing prescribing patterns in patients over 75 years taking 10 or more regular medications. You identify that 22% of patients in this group are taking a proton pump inhibitor (PPI) long-term without a documented indication. According to current evidence and guidance on deprescribing PPIs, which patient scenario would be the strongest indication for continuing long-term PPI therapy?
A. A 77-year-old woman taking aspirin 75mg daily for previous myocardial infarction with no history of gastrointestinal bleeding
B. An 80-year-old man with a history of duodenal ulcer 8 years ago, now asymptomatic, not taking NSAIDs or antiplatelet agents
C. A 78-year-old woman taking prednisolone 5mg daily for polymyalgia rheumatica and naproxen 500mg twice daily for osteoarthritis (Correct Answer)
D. A 76-year-old man with gastro-oesophageal reflux symptoms that resolved 2 years ago after lifestyle modifications
E. An 82-year-old woman taking alendronate for osteoporosis who had mild dyspepsia when starting treatment 5 years ago
Explanation: ***A 78-year-old woman taking prednisolone 5mg daily for polymyalgia rheumatica and naproxen 500mg twice daily for osteoarthritis***
- Co-administration of **NSAIDs (naproxen)** and **corticosteroids (prednisolone)** in elderly patients creates a multiplicative risk for **peptic ulceration** and gastrointestinal bleeding.
- Clinical guidelines strongly recommend long-term **gastroprotection** with a PPI for high-risk patients concurrently using these ulcerogenic medications.
*A 77-year-old woman taking aspirin 75mg daily for previous myocardial infarction with no history of gastrointestinal bleeding*
- Low-dose **aspirin monotherapy** without a history of GI bleeding or additional major risk factors is generally not an absolute indication for long-term PPI therapy.
- While age >65 years is a risk factor, it typically requires other co-factors or a history of GI bleeding for mandatory PPI co-prescription.
*An 80-year-old man with a history of duodenal ulcer 8 years ago, now asymptomatic, not taking NSAIDs or antiplatelet agents*
- A **remote history** of a duodenal ulcer in an asymptomatic patient not currently on high-risk medications is a prime candidate for **deprescribing**.
- Continuing a PPI indefinitely without active risk factors or symptoms increases the risk of side effects like **C. difficile infection** or bone fractures.
*A 76-year-old man with gastro-oesophageal reflux symptoms that resolved 2 years ago after lifestyle modifications*
- If **GORD symptoms** have been resolved for 2 years with lifestyle changes, the PPI should be stepped down or discontinued to see if **remission** is maintained.
- Long-term PPI use for resolved, mild GORD symptoms contributes to **polypharmacy** without clear clinical benefit and carries potential risks.
*An 82-year-old woman taking alendronate for osteoporosis who had mild dyspepsia when starting treatment 5 years ago*
- **Bisphosphonates** (alendronate) do not routinely require PPI co-prescription; PPIs can actually reduce calcium absorption and potentially worsen **osteoporosis** risks.
- Mild **dyspepsia** five years ago is not a valid indication for lifelong PPI use, especially if symptoms are no longer present or severe.
Question 18: A 76-year-old man with atrial fibrillation, heart failure (NYHA class II), type 2 diabetes, and benign prostatic hyperplasia attends for review. His medications include apixaban 5mg twice daily, bisoprolol, ramipril, metformin, empagliflozin, and tamsulosin. He reports two falls in the past month, both occurring at night when getting up to use the toilet. He describes feeling dizzy and nearly fainting. His lying blood pressure is 136/78 mmHg and standing blood pressure (after 1 minute) is 104/62 mmHg. What is the most likely cause of his orthostatic hypotension and falls?
A. Additive effect of bisoprolol and ramipril causing excessive blood pressure reduction
B. Apixaban causing occult bleeding and anemia leading to postural symptoms
C. Empagliflozin causing volume depletion through glycosuria and natriuresis
D. Tamsulosin causing alpha-blockade and venous pooling on standing (Correct Answer)
E. Nocturnal polyuria from poorly controlled diabetes causing dehydration
Explanation: ***Tamsulosin causing alpha-blockade and venous pooling on standing***- **Tamsulosin** is an **alpha-1 adrenergic antagonist** used for **benign prostatic hyperplasia (BPH)**, which causes **vasodilation** in both arterial and venous beds.- This leads to **venous pooling** upon standing, reducing **venous return** and **cardiac output**, resulting in a significant **orthostatic drop** in blood pressure (32 mmHg systolic in this case), especially when changing position rapidly from lying down.
*Additive effect of bisoprolol and ramipril causing excessive blood pressure reduction*
- While **bisoprolol** (beta-blocker) and **ramipril** (ACE inhibitor) lower overall blood pressure, the patient's **lying blood pressure** (136/78 mmHg) is not excessively low, suggesting generalized hypotension is not the primary cause.
- The pronounced **postural drop** is more indicative of a **failure of autonomic compensation** on standing rather than a simple additive reduction in baseline blood pressure.
*Apixaban causing occult bleeding and anemia leading to postural symptoms*
- **Apixaban** is an **anticoagulant** and does not directly affect vascular tone or cause orthostatic hypotension as a primary side effect.
- While **occult bleeding** and subsequent **anemia** can cause dizziness and postural symptoms, the specific acute and pronounced drop upon standing, especially at night, points more strongly to an immediate vascular effect.
*Empagliflozin causing volume depletion through glycosuria and natriuresis*
- **Empagliflozin**, an SGLT2 inhibitor, can cause **osmotic diuresis** and lead to mild **volume depletion**, potentially contributing to hypotension.
- However, the magnitude of the **postural drop** (32 mmHg systolic) is more characteristic of a significant failure of **vasoconstriction** upon standing (as seen with alpha-blockers) rather than simply mild hypovolemia.
*Nocturnal polyuria from poorly controlled diabetes causing dehydration*
- **Nocturnal polyuria** from poorly controlled diabetes can lead to **dehydration** and postural symptoms, especially at night.
- The patient is on **metformin** and **empagliflozin**, indicating treatment for diabetes, and the clinical presentation is dominated by the acute failure of the baroreceptor reflex from **tamsulosin** rather than chronic dehydration, which would typically cause a lower baseline BP and possibly tachycardia.
Question 19: You are conducting a medication review for a 71-year-old woman with multimorbidity who takes 12 regular medications. She reports good adherence but admits she sometimes gets confused about which tablets to take and when. Her medication regimen includes twice-daily, three times daily, and once-daily medications, with some to be taken with food and others on an empty stomach. Which intervention has the strongest evidence base for improving medication adherence in patients with complex regimens?
A. Prescribing all medications as once-daily preparations where possible (Correct Answer)
B. Providing a multi-compartment compliance aid (dosette box)
C. Arranging weekly telephone calls from the practice pharmacist
D. Giving written information sheets about each medication
E. Setting up automated text message reminders for each dose
Explanation: ***Prescribing all medications as once-daily preparations where possible***- Reducing **dosing frequency** through regimen simplification has the strongest evidence base for improving adherence by decreasing the **cognitive burden** on the patient.- Studies consistently show that **once-daily dosing** results in significantly higher adherence compared to twice-daily or more frequent schedules across various chronic conditions.*Providing a multi-compartment compliance aid (dosette box)*- While widely used, the evidence for **dosette boxes** is surprisingly mixed and they do not fundamentally address the underlying problem of **regimen complexity**.- These aids carry risks, such as **drug stability issues** and potential confusion if the patient's medication is changed frequently.*Arranging weekly telephone calls from the practice pharmacist*- Although pharmacist-led interventions provide support, **telephone follow-ups** have less robust evidence for long-term adherence compared to simplifying the regimen itself.- This intervention is **resource-intensive** and may not be sustainable for patients managing long-term, multi-drug therapies.*Giving written information sheets about each medication*- **Written information** alone has a limited impact on adherence behaviors and may actually increase confusion in patients with already complex 12-drug regimens.- Standardized sheets often fail to address **functional barriers** to taking medication, such as timing and frequency of doses.*Setting up automated text message reminders for each dose*- **Text message reminders** show some promise, but their effectiveness is lower in **elderly populations** who may face technological or sensory barriers.- For a patient taking medications multiple times a day, frequent alerts can lead to **alarm fatigue** and may not solve the confusion regarding food requirements.
Question 20: A 70-year-old man attends for a medication review. He has COPD (post-bronchodilator FEV1 44% predicted), ischaemic heart disease, peripheral arterial disease, and has had two previous strokes. His current medications include aspirin, clopidogrel, atorvastatin, bisoprolol, ramipril, tiotropium, and salbutamol. He smoked 30 cigarettes daily until his last stroke 3 years ago and has not smoked since. What is the most appropriate modification to his antiplatelet therapy at this stage?
A. Continue dual antiplatelet therapy indefinitely given his high vascular risk
B. Stop clopidogrel and continue aspirin monotherapy (Correct Answer)
C. Stop aspirin and continue clopidogrel monotherapy
D. Stop both antiplatelet agents and start rivaroxaban 2.5mg twice daily
E. Add dipyridamole modified-release 200mg twice daily to the current regimen
Explanation: ***Stop clopidogrel and continue aspirin monotherapy***
- Long-term **dual antiplatelet therapy (DAPT)** beyond 6-12 months is generally not indicated for stable secondary prevention after a vascular event due to a significant increase in **bleeding risk**.
- For this patient with stable ischemic heart disease and past strokes (over 3 years ago), **aspirin monotherapy** is the standard, effective choice for long-term reduction of major adverse cardiovascular and cerebrovascular events.
*Continue dual antiplatelet therapy indefinitely given his high vascular risk*
- While the patient has a high vascular risk, the **risk-benefit ratio** of indefinite DAPT does not favor continued dual therapy due to the increased risk of **major hemorrhage** in an elderly patient with multiple comorbidities.
- Current guidelines recommend DAPT for a limited period (e.g., 6-12 months) post-event, after which **monotherapy** is preferred for long-term secondary prevention.
*Stop aspirin and continue clopidogrel monotherapy*
- While **clopidogrel monotherapy** is a valid alternative for secondary prevention, especially post-stroke, there is no specific indication to stop **aspirin** in this patient who also has **ischemic heart disease** and **peripheral arterial disease**, for which aspirin is well-established.
- Continuing aspirin is a standard practice for multi-system vascular protection, and switching without a specific intolerance or indication is generally unnecessary.
*Stop both antiplatelet agents and start rivaroxaban 2.5mg twice daily*
- Low-dose **rivaroxaban** (COMPASS trial regimen) is indicated in combination with **aspirin**, not as a replacement for all antiplatelets, in very high-risk stable coronary or peripheral artery disease to further reduce MACE.
- This regimen is not indicated for isolated stroke prevention, and there is no mention of **atrial fibrillation** which would warrant full-dose anticoagulation.
*Add dipyridamole modified-release 200mg twice daily to the current regimen*
- Adding **dipyridamole** to existing dual antiplatelet therapy (aspirin + clopidogrel) would result in triple antiplatelet therapy, which is associated with a significantly increased **bleeding risk** and is not recommended for stable secondary prevention.
- While aspirin-dipyridamole combination is an option for secondary stroke prevention, it is not typically combined with clopidogrel, and adding a third agent would increase **polypharmacy** without clear additional benefit in this stable patient.
